Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Joseph F Merola,
Frank Behrens,
Marina Magrey,
Liang Chen,
Derek Haaland,
Koji Kato,
Mitsumasa Kishimoto,
Patrick Zueger,
Aileen L Pangan,
Cesar Pacheco-Tena,
John Liu,
Yuanyuan Duan,
Ralph Lippe
Affiliations
Joseph F Merola
Department of Rheumatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Frank Behrens
3 CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany
Marina Magrey
School of Medicine at Metrohealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
Liang Chen
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Derek Haaland
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Koji Kato
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Mitsumasa Kishimoto
Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Patrick Zueger
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Aileen L Pangan
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Cesar Pacheco-Tena
Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico
John Liu
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Yuanyuan Duan
Department of Immunology, AbbVie Inc, North Chicago, Illinois, USA
Ralph Lippe
Department of Immunology, AbbVie Deutschland GmbH & Co KG, Wiesbaden, Hesse, Germany
